Physician profile
Peter A Andrews
NPI 1275541468
$2,445.16
in general payments reported to CMS, 2019-2025
17 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $520 · 2021: $39.86 · 2022: $185 · 2023: $220 · 2024: $85.08 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $946.05 | 2019-2025 | |
| Novo Nordisk INC | $253.04 | 2019-2020 | |
| Abbvie INC. | $242.44 | 2020-2025 | Ubrelvy |
| Lilly USA, LLC | $213.57 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.83 | 2019-2020 | |
| Allergan, INC. | $147.11 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $123.38 | 2019 | |
| Amgen INC. | $79.42 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.81 | 2019-2020 | |
| Amarin Pharma, INC. | $31.71 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.77 | 2019 | |
| Genentech USA, INC. | $17.38 | 2019 | |
| Glaxosmithkline, LLC. | $15.64 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.